Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study
PLOS One · 2025
DOI: 10.1371/journal.pone.0318483 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Iman Menbari Oskouie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Flutamide, Selenium, Prostatic Neoplasms, Nanoparticles. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Objective of the study was to evaluate the therapeutic potential of selenium nanoparticles (SeNPs) in combination with flutamide for treating prostate cancer (PCa) cell lines. The goal was to reduce the dosage of flutamide to decrease its side effects, especially hepatotoxicity. Materials and methods PC3, LnCAP, and DU145 cell lines were treated with varying concentrations of SeNPs and Flutamide to determine IC50 values using the MTT assay. Subsequently, the IC50 concentration of flutamide was reduced by 50% and different concentrations of SeNPs were added to determine new IC50 concentrations of the combinations. Annexin-V/ PI staining was performed to assess the apoptosis rate. The DNA cell cycle was analyzed using the PI staining technique. Migration, proliferative capability, and nucleus morphology of the cells were evaluated through the scratch-wound assay, colony-forming assay, and Hoechst staining, respectively. The expression of SNAIL , KLK3 , E-cadherin , VEGF-C , HIF-1α , Bcl2 , and BAX were examined using real-time PCR.
Results
All treated groups significantly increased early and late apoptosis rate of the PCa cell lines, and induced SubG1/G1 arrest in the cell cycle assay, compared to the control group. Significant inhibition of migration potential and colony formation was observed in all treated groups. Our results suggest that the combination group (50% decrease of Flutamide dosage) treatment upregulated apoptosis-related genes and KLK3 , and downregulated genes involved in angiogenesis and proliferation similar to Flutamide alone (p > 0.05).
Conclusion
It is suggested that simultaneous administration of SeNPs and flutamide could potentially reduce the effective dosage of flutamide and decrease its adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Ronash Technology Pars Company (AMINBIC), Tehran University Science and Technology Park, North Campus of Tehran University, Tehran, Iran.
- Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Fatemeh Khatami, Seyed Mohammad Kazem Aghamir
Zitieren
APA
Menbari Oskouie, I., Khatami, F., Shiralizadeh Dezfuli, A., Mashhadi, R., Mirzaei, A., Hashemi Dougaheh, S. N., Azodian Ghajar, H., Heshmat, R., & Aghamir, S. M. K. (2025). Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study. PLOS One. https://doi.org/10.1371/journal.pone.0318483
Vancouver
Menbari Oskouie I, Khatami F, Shiralizadeh Dezfuli A, Mashhadi R, Mirzaei A, Hashemi Dougaheh SN, et al. Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study. PLOS One. 2025. doi:10.1371/journal.pone.0318483
BibTeX
@article{MenbariOskouie2025,
author = {Menbari Oskouie, Iman and Khatami, Fatemeh and Shiralizadeh Dezfuli, Amin and Mashhadi, Rahil and Mirzaei, Akram and Hashemi Dougaheh, Seyedeh Negin and Azodian Ghajar, Helia and Heshmat, Ramin and Aghamir, Seyed Mohammad Kazem},
title = {Reducing the effective dosage of flutamide on prostate cancer cell lines through combination with selenium nanoparticles: An in-vitro study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0318483}
}
EUVIMED